Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M, et al. Among authors: baldini l. J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124807 Clinical Trial.
ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi. Gobbi PG, et al. Among authors: baldini l. J Clin Oncol. 2005 Dec 20;23(36):9198-207. doi: 10.1200/JCO.2005.02.907. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172458 Clinical Trial.
Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.
Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M. Iannitto E, et al. Among authors: baldini l. Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034. Clin Lymphoma Myeloma. 2009. PMID: 19406724 Clinical Trial.
Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi.
Mannina D, Luminari S, Dondi A, Polimeno G, Baldini L, Stelitano C, Merli F, Dell'Olio M, Gobbi PG, Giglio G, Barbolini E, Brugiatelli M, Federico M. Mannina D, et al. Among authors: baldini l. Leuk Lymphoma. 2010 Mar;51(3):422-9. doi: 10.3109/10428190903518352. Leuk Lymphoma. 2010. PMID: 20038237
Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
Ferrario A, Merli F, Luminari S, Stelitano C, Mannina D, Russo M, Mazza P, Marcheselli L, Goldaniga MC, Federico M, Baldini L; Gruppo Italiano per lo Studio dei Linfomi. Ferrario A, et al. Among authors: baldini l. Ann Hematol. 2011 Mar;90(3):323-30. doi: 10.1007/s00277-010-1067-1. Epub 2010 Sep 17. Ann Hematol. 2011. PMID: 20848104 Clinical Trial.
Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi.
Chisesi T, Bellei M, Luminari S, Montanini A, Marcheselli L, Levis A, Gobbi P, Vitolo U, Stelitano C, Pavone V, Merli F, Liberati M, Baldini L, Bordonaro R, Pesce EA, Federico M. Chisesi T, et al. Among authors: baldini l. J Clin Oncol. 2011 Nov 10;29(32):4227-33. doi: 10.1200/JCO.2010.30.9799. Epub 2011 Oct 11. J Clin Oncol. 2011. PMID: 21990405 Clinical Trial.
Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, Stelitano C, Musso M, Baldini L, Galimberti S, Angrilli F, Polimeno G, Scalzulli PR, Ferrari A, Marcheselli L, Federico M. Merli F, et al. Among authors: baldini l. J Clin Oncol. 2016 Apr 10;34(11):1175-81. doi: 10.1200/JCO.2015.62.4817. Epub 2015 Dec 28. J Clin Oncol. 2016. PMID: 26712220 Free article. Clinical Trial.
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.
Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P. Baldini L, et al. J Clin Oncol. 2005 Jul 20;23(21):4662-8. doi: 10.1200/JCO.2005.06.147. J Clin Oncol. 2005. PMID: 16034042
528 results